Therapeutic Drug Monitoring (TDM) of anti–tumor necrosis factor (TNF) therapies such as Adalimumab has increased significantly over time as clinicians seek to optimize treatment outcomes for patients with inflammatory bowel disease (IBD).
Even when medication is administered subcutaneously by the patient, there is a need to check trough levels prior to dosing to ensure therapeutic levels are maintained. However, traditional testing methods often require days or even weeks to deliver results.
Procise ADL allows true point-of-care testing of Adalimumab levels in under 5 minutes using finger-stick blood. During a standard clinical visit, physicians or technicians can immediately assess drug levels and adjust medication dosing accordingly.
This enables treatment optimization at the patient’s very next injection, rather than weeks or months later, improving clinical outcomes and patient confidence.
| Parameter | Details |
|---|---|
| Sample Types | Finger prick whole blood, venous blood, or serum |
| Reportable Range | 1.3 µg/mL – 51.5 µg/mL |
| Time to Results | Less than 5 minutes |
| Stability | 2 years at room temperature |
| Validated for | Adalimumab (Humira®, Amgevita®, and Imraldi®) |
Calibrated against WHO standard.